New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
09:06 EDTACADACADIA price target raised to $42 from $28 at Piper Jaffray
Piper Jaffray raised its price target for ACADIA Pharmaceuticals to $42 citing the company's pipeline progress following its Q4 results. The firm keeps an Overweight rating on the stock.
News For ACAD From The Last 14 Days
Check below for free stories on ACAD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
09:03 EDTACADACADIA receives FDA breakthrough therapy designation for Nuplazid
ACADIA Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to NUPLAZID for the treatment of Parkinsonís disease psychosis. NUPLAZID is a selective serotonin inverse agonist and, if approved, will establish a new and distinctly different pharmacological approach to treating psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinsonís disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application. ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.
August 28, 2014
09:01 EDTACADACADIA says FDA provisionally accepts trade name Nuplasid for pimavanserin
ACADIA Pharmaceuticals announced that the U.S. Food and Drug Administration has provisionally accepted the trade name ďNUPLAZIDĒ for pimavanserin. NUPLAZID is a selective serotonin inverse agonist and, if approved, will represent the first in a new class of drugs to treat psychosis. NUPLAZID has successfully completed a pivotal Phase III trial in Parkinsonís disease psychosis, which the FDA has agreed can serve as the basis, together with supportive data from other studies, for a New Drug Application. ACADIA plans to submit the NUPLAZID NDA to the FDA near the end of this year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use